Peter Zdziarski: Protecting Patient Data in the Rare Disease Community
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
”As a patient with a rare disease, my data is highly valuable.
If you are part of the Glanzmann Thrombasthenia community or the rare disease community at large, yours is too!
Before taking part in one of the many surveys out there, a few things to keep in mind:
- What will happen to your data, how it will be shared, and for how long it will be retained.
This establishes where your data goes and how long it lives outside of your control.
In rare disease communities, even anonymous data can be sensitive and have a long shelf life.
- If ‘strong legal or liability language’ seems out of proportion to a ‘simple survey.’
Legalistic language, disclaimers, or liability notices may indicate a higher risk or more extensive data use than the survey itself suggests.
This should trigger a closer look.
- Who the research partner is and what they gain from the data.
Knowing whether the partner is academic, non-profit, or pharmaceutical can help understand the intent and whether the main advantage is patient-centered, commercial, or a combination of both.
That being said, surveys are important.
When conducted in a transparent and respectful manner, they can increase awareness, inform better research, and give a voice to patients with rare diseases who are often unheard.”
Stay updated with Hemostasis Today.
-
Feb 15, 2026, 10:56Don’t Miss PNH: Clinical Practice From ISTH – Medscape
-
Feb 15, 2026, 10:52Awareness and Research on Factor V Deficiency Are Critical – EHC
-
Feb 15, 2026, 10:31Michiel Voet: The Price Tag of a Whole Blood Strategy
-
Feb 15, 2026, 10:26Sifat Jubaira: K₂-EDTA vs K₃-EDTA – Same Anticoagulant, Very Different Accuracy
-
Feb 15, 2026, 09:29Gevorg Tamamyan: Childhood Cancer is Curable. Inequity Is Not
-
Feb 15, 2026, 07:24Ekaterina Balaian Extends Sincere Gratitude to The Team at The Yeolyan Hematology and Oncology Center
-
Feb 15, 2026, 07:10Brijesh Kumar: Stroke Rehabilitation Needs Scalable and Evidence-Based Models
-
Feb 15, 2026, 06:58Reza Hosseini Ghomi: A New Tool Predicts The Onset of Dementia After Stroke
-
Feb 15, 2026, 06:45Mohamed Rawy: Clinical Pearls of Clopidogrel